Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Non Cirrhotic Portal Hypertension (NCPH) presenting to our Liver Diseases Follow-up Clinic with history of hemetemesis and/or malena within the past 6 weeks and proven to have esophageal varices as the bleeding source on upper GI endoscopy~Exclusion Criteria:~* A history of surgery for portal hypertension~* Patients already on a EST, EVL, or glue injection program before presenting to our hospital~* Patients already on beta blockers for primary prophylaxis of variceal bleed~* Severe cardiopulmonary or renal disease~* Bradycardia (basal heart rate, \<50 beats per minute \[bpm\]) or complete heart block~* A history of severe side effects or contraindications to β- blockers, like bronchial asthma, diabetes mellitus, heart failure, peripheral vascular disease, prostatic hypertrophy, or arterial hypotension (systolic blood pressure \<90 mm Hg)~* Refusal to give informed written consent to participate in the trial~* Patients bleeding from gastric varices or Portal Hypertensive Gastropathy (PHG).~* Patients who had a failure of primary hemostasis during acute bleed were also excluded.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Endoscopic Variceal Ligation (Type: ACTIVE_COMPARATOR): endoscopic therapy to obliterate varices
- Propranolol (Type: ACTIVE_COMPARATOR): drugs to decrease portal pressure

Based on this trial design, predict the completion outcome and termination type (if applicable).